Advancing oncolytic virus therapy by understanding the biology
- 8 March 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 18 (4), 197-198
- https://doi.org/10.1038/s41571-021-00490-4
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspectiveCancer Cell, 2021
- Clinical landscape of oncolytic virus research in 2020Journal for ImmunoTherapy of Cancer, 2020
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialAnnals of Surgical Oncology, 2016
- Oncolytic viruses: a new class of immunotherapy drugsNature Reviews Drug Discovery, 2015
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of Clinical Oncology, 2015
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade ImmunotherapyScience Translational Medicine, 2014
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV MelanomaAnnals of Surgical Oncology, 2009